An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2018
At a glance
- Drugs CYP 001 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Sponsors Cynata Therapeutics
- 27 Feb 2018 Results from the Primary Evaluation Period published in the Cynata Therapeutics Media Release
- 27 Feb 2018 According to a Cynata Therapeutics media release, the Primary Evaluation Period has been completed for the first cohort of patients in this trial.
- 24 Jan 2018 According to a Cynata Therapeutics media release, the first patient in Cohort B and the ninth patient overall has been treated in this trial. A total of 8 patients are expected to participate in Cohort B.